CacheTech Inc. Has $544,000 Position in Pfizer Inc. (NYSE:PFE)

CacheTech Inc. cut its holdings in Pfizer Inc. (NYSE:PFE) by 9.1% in the 3rd quarter, Holdings Channel.com reports. The firm owned 18,785 shares of the biopharmaceutical company’s stock after selling 1,882 shares during the quarter. CacheTech Inc.’s holdings in Pfizer were worth $544,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. LGT Group Foundation raised its holdings in shares of Pfizer by 2.5% during the second quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock worth $20,786,000 after acquiring an additional 18,274 shares during the period. Creative Planning raised its stake in shares of Pfizer by 17.1% in the 3rd quarter. Creative Planning now owns 1,820,731 shares of the biopharmaceutical company’s stock valued at $52,692,000 after purchasing an additional 266,167 shares during the period. ORG Partners LLC lifted its holdings in shares of Pfizer by 1,729.9% in the second quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock valued at $1,327,000 after purchasing an additional 44,458 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its position in shares of Pfizer by 10.3% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 256,460 shares of the biopharmaceutical company’s stock worth $7,422,000 after buying an additional 23,928 shares during the period. Finally, Everett Harris & Co. CA raised its position in Pfizer by 21.7% in the 3rd quarter. Everett Harris & Co. CA now owns 218,344 shares of the biopharmaceutical company’s stock valued at $6,319,000 after buying an additional 38,870 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have weighed in on PFE. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. UBS Group boosted their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Citigroup started coverage on Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 price target for the company. Finally, Evercore ISI raised Pfizer to a “strong-buy” rating in a research report on Wednesday. Eight investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.58.

Pfizer Stock Down 0.8 %

Pfizer stock opened at $28.08 on Friday. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $31.54. The stock has a market cap of $159.12 billion, a P/E ratio of 37.95, a P/E/G ratio of 0.90 and a beta of 0.67. The company’s 50-day moving average price is $29.03 and its two-hundred day moving average price is $28.57. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.40% and a net margin of 7.07%. The business had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same period last year, the firm posted ($0.17) EPS. The firm’s revenue for the quarter was up 31.2% compared to the same quarter last year. As a group, analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 5.98%. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Insiders Place Their Bets

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.